LATEST

• BUSINESS Lilly Confirms Orforglipron Diabetes Filings in US, Japan
  August 7, 2026

• BUSINESS Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
  August 7, 2026

• REGULATORY Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
  August 7, 2026

• BUSINESS Meiji Pharma Drops Hiyasta Development in B-Cell NHL
  August 7, 2026

• BUSINESS Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
  August 7, 2026

• REGULATORY Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
  August 6, 2026

• REGULATORY Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
  August 6, 2026

• REGULATORY Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
  August 6, 2026

• REGULATORY Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
  August 6, 2026

• REGULATORY Fujifilm’s Meniscus Regenerative Therapy to Be Priced as Medical Device
  August 6, 2026

• BUSINESS AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
  August 5, 2026

• BUSINESS AstraZeneca Sees Broad Pipeline, AI Powering 50-Plus Approval Goal
  August 5, 2026

• REGULATORY CEA Review Group Debates Draft Report, Eyes August 18 Wrap-Up
  August 5, 2026

• BUSINESS Voyxact PIII Data Confirm Kidney Function Stabilization in IgAN
  August 5, 2026

• BUSINESS Perioperative Imfinzi Seen Advancing Gastric Cancer Care: Oncologist
  August 5, 2026

• BUSINESS Teijin Still Seeking “Best Owner” for Legacy Drug Portfolio
  August 5, 2026

• BUSINESS Rohto Takes Control of OPBio to Bolster Marine Biotech R&D
  August 5, 2026

• BUSINESS Specialist Hails Zepbound’s OSA Nod as Major Treatment Advance
  August 5, 2026

• BUSINESS Gotham Questions Sumitomo Accounting; Company Rejects Claims
  August 5, 2026

• BUSINESS Opdivo Gets South Korea Nod for Resectable NSCLC
  August 5, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »